AGNCP Q1 2026 Earnings Preferred Shares Benefit as EPS Exceeds Estimates by 145 ALGS Q1 2026 Earnings NarrowerthanExpected Loss as Aligos Therapeutics Advances Pipeline Monopar Therapeutics Q1 2026 Earnings Narrower Loss Surprises Market Nyxoah NYXH Q1 2026 Earnings NarrowerThanExpected Loss as PreRevenue Biotech Advances Sleep Apnea Pipeline CNTA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues RD Investment CRDL Q4 2025 Earnings Narrower Than Expected Loss as Cardiol Therapeutics Advances Clinical Pipeline